Keyphrases
Therapeutic Candidates
100%
Huntington's Disease
100%
Polyglutamine Aggregation
25%
AK-1
25%
Huntingtin Aggregates
25%
Therapeutic Leads
25%
Neuroprotective
25%
Neurodegeneration
25%
Clinical Trials
25%
Neurodegenerative Diseases
25%
Drug-like
25%
Structural Analogues
12%
Acid Derivatives
12%
Aggregate Size
12%
Penetration Property
12%
Pharmacokinetic Assay
12%
Brain Pharmacokinetics
12%
Hit Optimization
12%
Abnormal Proteins
12%
Fruit Fly Model
12%
Blood-brain Barrier Penetration
12%
ADMET Studies
12%
Trinucleotide
12%
Chorea
12%
In Silico Calculations
12%
ADMET Profiling
12%
Knock-in Mouse Model
12%
Disease-modifying Therapy
12%
Autosomal Dominant
12%
IND Application
12%
Medicinal Chemistry
12%
Small Molecule Inhibitors
12%
Neuron Loss
12%
High-throughput Screening
12%
Progressive Dementia
12%
Polyglutamine
12%
Public Health
12%
Oral Bioavailability
12%
Motor Performance
12%
IND-enabling Study
12%
Mouse Brain Slices
12%
Striatal Neurons
12%
Misfolding
12%
Disease Progression
12%
Neuropathology
12%
CAG Repeat
12%
Potential Therapeutics
12%
Mouse Model
12%
Disease Course
12%
Genetic Defects
12%
Therapeutic Promises
12%
Pharmacology, Toxicology and Pharmaceutical Science
Huntington Chorea
100%
Polyglutamine
37%
Diseases
37%
Absorption-Distribution-Metabolism-Excretion Toxicity
25%
Nerve Degeneration
25%
Clinical Trial
25%
Neuroprotective Agent
25%
Disease Model
25%
Huntingtin
25%
Pharmacokinetics
25%
Fruit Fly Model
12%
Mouse Model
12%
High-Throughput Screening
12%
Pharmaceutical Chemistry
12%
Genetic Disorder
12%
Disease Exacerbation
12%
Disease Course
12%
Guanosine Phosphate
12%
Trinucleotide
12%
Bioavailability
12%
Chorea
12%
Blood-Brain Barrier
12%
Neuroscience
Huntington's Disease
100%
Polyglutamine
37%
Huntingtin
25%
Neurodegenerative Disorder
25%
Neuroprotective Agent
25%
Neurodegeneration
25%
Pharmacokinetics
25%
In Vivo
12%
CAG Repeat
12%
Guanosine Monophosphate
12%
Blood Brain Barrier
12%
Chorea
12%
Brain Slice
12%
Trinucleotide
12%
Mouse Brain
12%